Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 2021

View Archived Issues

HER2 CAR-NK cells show preclinical antitumor activity without off-target cytotoxicity

TGF-beta-mediated mTOR inhibition preserves cellular metabolism of precursors of exhausted T cells

New prosthetic valvular graft infection model shows benefit of adjunctive fibrinolytic treatment

Model of steroid-resistant neutrophilic asthma developed to test treatments

GFAP a biomarker in frontotemporal lobar degeneration and primary psychiatric disorders

TYK Medicines divulges new Ret inhibitors

Wigen Biomedicine Technology presents KRAS mutant inhibitors

FDA accepts IND application for phase IIa study of Quilience as treatment of narcolepsy

UCB discloses new FCER1A mutant inhibitors

FDA clears IND for phase I trial of SYSA-1801 in advanced pancreatic cancer

Phase I trial investigates SHJ-002 for myopia in pediatric subjects

ABBV-CLS-7262 studied in phase I for ALS

BIX-119 leads to improved clinical benefit through blocking both IL-17 and IL-22

Scioto opens phase I study of SB-121 in participants with autistic disorder

New neonatal murine model of Listeria monocytogenes meningitis developed

Clarity recruits patients with prostate cancer to evaluate PET imaging with [64Cu]SAR-bisPSMA

Discovery of novel selective Axl inhibitor with antitumor activity in vivo

Phase II/III trial studies SHR-1701 with BP-102 and XELOX in first-line metastatic colorectal cancer

U.S. phase II trial explores use of Velexbru in primary central nervous system lymphoma

CytoDyn reports preliminary data on leronlimab in metastatic TNBC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...